Market Overview

The gout therapeutics market was valued at USD 3.13 billion in 2024 and is projected to grow at a CAGR of 7.0% from 2025 to 2034, according to Polaris Market Research. Gout is a form of inflammatory arthritis caused by uric acid crystal deposition. The market covers pharmaceutical products and treatment approaches that manage and relieve symptoms, including urate-lowering therapies, anti-inflammatories, and novel biologics designed to prevent flare-ups and reduce uric acid levels. For pharmaceutical strategists, investors, and healthcare suppliers, the figures below outline where opportunity is concentrating.

Market Size and Forecast

The market is expected to reach USD 3.34 billion in 2025 and USD 6.15 billion by 2034. North America was the largest regional market in 2024. Rising gout incidence linked to sedentary lifestyles, alcohol consumption, and obesity is driving demand for effective gout treatment, while the correlation between metabolic syndrome and gout is intensifying treatment needs across primary and chronic care.

Key Growth Drivers

Lifestyle disorders are a central factor. Purine-rich diets and metabolic syndrome often raise uric acid levels, leading to frequent and painful attacks. Physicians increasingly recognize the long-term impact of untreated hyperuricemia, prompting earlier diagnosis and intervention, and pharmaceutical innovation is moving toward safer, more effective urate-lowering options.

Demographics add further pressure. According to the World Health Organization, about 16.7% of the global population will be aged 60 and older by 2030, and this group is projected to double to approximately 2.1 billion by 2050. Older adults are more likely to develop gout and often need consistent uric acid management alongside care for cardiovascular and renal complications. Within this long-term category, established gout medication options such as allopurinol remain part of the clinical conversation, while developers invest in patient-friendly formulations and lower-risk therapies.

One restraint is the high cost of advanced therapies and limited reimbursement in emerging markets, which restricts patient access.

Segment Insights

By disease condition, chronic gout held the largest revenue share in 2024, reflecting demand for long-term therapies that control uric acid and prevent flare-ups. Acute gout is gaining traction because patients need immediate relief during flares.

By drug class, NSAIDs dominated with roughly 43% of revenue share in 2024, owing to rapid action against inflammation and pain. Urate-lowering agents, including xanthine oxidase inhibitors and uricosurics, are expected to register a significant CAGR from 2025 to 2034 because they address the underlying cause of hyperuricemia rather than symptoms alone.

By distribution channel, retail pharmacy held the largest share in 2024, supported by accessibility and high prescription fulfillment, while online pharmacy is gaining momentum through digital health platforms and home delivery.

Browse In-depth Market Research Report:

https://www.polarismarketresearch.com/industry-analysis/gout-therapeutics-market 

Regional Outlook

North America accounted for roughly 50% of revenue in 2024, supported by strong healthcare infrastructure, early diagnosis, and wide access to rheumatology care, with the U.S. leading the region. Asia Pacific is projected to post the highest CAGR from 2025 to 2034 as awareness, healthcare access, and lifestyle-related hyperuricemia increase. China is growing rapidly due to dietary shifts, higher alcohol consumption, and an aging population.

Competitive Landscape

Companies are pursuing innovation pipelines, strategic alliances, joint ventures, and acquisitions to access novel candidates and broaden portfolios. In July 2025, Eisai launched URECE in China for gout. Key players include:

• Arrowhead Pharmaceuticals, Inc.
• AstraZeneca
• Eisai Co., Ltd.
• GSK plc.
• Merck & Co., Inc.
• Novartis AG
• Regeneron Pharmaceuticals Inc.
• Takeda Pharmaceutical Company Limited
• Teijin Pharma Ltd.
• Zydus Group

Conclusion

The gout therapeutics market is on course to grow from USD 3.13 billion in 2024 to USD 6.15 billion by 2034 at a 7.0% CAGR. Chronic gout, NSAIDs, and retail pharmacy lead today, while urate-lowering agents, online pharmacy, and Asia Pacific point to the next phase of growth. Companies that combine targeted therapies with improved access and affordability will be best positioned in this expanding market.

More Trending Latest Reports By Polaris Market Research:

Hadron Therapy Market Forecast

Medical Radiation Shielding Market Analysis

Optical Imaging Systems Market Opportunities

Rye Market Trends

Packaged Salad Market Size

Coworking Spaces Market Share

Pessary Market Growth

High Altitude Platform Market Forecast

Sea Moss Market Analysis